Theravance Announces Clinical Results in the LAMA Respiratory Program for the...
Marketwire via Yahoo! Finance: 4 views since Monday, July 14, 2008 at 04:05 PM
Theravance, Inc. today announced the results from a Phase 1 study designed to assess the safety, tolerability and pharmacokinetics of an investigational inhaled long-acting muscarinic antagonist, GSK1160724/TD-4208, for the treatment of chronic obstructive pulmonary disease.

Published in: Randomized Things